17.07.2014 • News

Luciano Rossetti Moves from Merck to Merck

Merck Serono, the biopharmaceutical division of Germany's Merck KGaA has appointed Luciano Rossetti as executive vice president and global head of research & development with effect from July 2.

Rossetti most recently was Senior Vice President Late Stage Development at US pharmaceutical producer Merck Sharp & Dohme, where he was responsible for the entire clinical development from Phase II to Phase V across all therapeutic areas.

The new R&D chief will be based in Billerica, outside Boston, Massachusetts, in the US, one of Merck Serono's four global R&D hubs, and will share his time between Merck's headquarters in Darmstadt, Germany, and Billerica.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

most read